LSE:CSRT

Stock Analysis Report

Executive Summary

Consort Medical plc operates as a one-stop developer and manufacturer of drugs and premium drug delivery devices in Europe, the United States, the United Kingdom, and internationally.


Snowflake Analysis

Reasonable growth potential and slightly overvalued.


Similar Companies

Share Price & News

How has Consort Medical's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: CSRT's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-1.0%

CSRT

-3.3%

GB Medical Equipment

-2.2%

GB Market


1 Year Return

12.1%

CSRT

-3.7%

GB Medical Equipment

-25.9%

GB Market

Return vs Industry: CSRT underperformed the UK Medical Equipment industry which returned 30.4% over the past year.

Return vs Market: CSRT exceeded the UK Market which returned 6.1% over the past year.


Shareholder returns

CSRTIndustryMarket
7 Day-1.0%-3.3%-2.2%
30 Day-2.0%-18.4%-21.7%
90 Day-4.3%-22.3%-29.6%
1 Year14.2%12.1%-1.9%-3.7%-22.2%-25.9%
3 Year4.6%-1.3%1.6%-4.3%-16.1%-26.6%
5 Year24.3%12.9%27.3%15.2%-4.6%-26.2%

Price Volatility Vs. Market

How volatile is Consort Medical's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Consort Medical undervalued compared to its fair value and its price relative to the market?

18.8%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: CSRT (£10.05) is trading below our estimate of fair value (£12.38)

Significantly Below Fair Value: CSRT is trading below fair value, but not by a significant amount.


Price To Earnings Ratio

PE vs Industry: CSRT is poor value based on its PE Ratio (126.5x) compared to the Medical Equipment industry average (33.6x).

PE vs Market: CSRT is poor value based on its PE Ratio (126.5x) compared to the UK market (18.5x).


Price to Earnings Growth Ratio

PEG Ratio: CSRT is poor value based on its PEG Ratio (3.2x)


Price to Book Ratio

PB vs Industry: CSRT is good value based on its PB Ratio (2.2x) compared to the GB Medical Equipment industry average (3.3x).


Next Steps

Future Growth

How is Consort Medical forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?

39.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: CSRT's forecast earnings growth (39.3% per year) is above the savings rate (0.5%).

Earnings vs Market: CSRT's earnings (39.3% per year) are forecast to grow faster than the UK market (12.2% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: CSRT's revenue (3.6% per year) is forecast to grow faster than the UK market (3.5% per year).

High Growth Revenue: CSRT's revenue (3.6% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: CSRT's Return on Equity is forecast to be low in 3 years time (14.6%).


Next Steps

Past Performance

How has Consort Medical performed over the past 5 years?

2.7%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: CSRT has a large one-off loss of £23.6M impacting its October 31 2019 financial results.

Growing Profit Margin: CSRT's current net profit margins (1.3%) are lower than last year (5.4%).


Past Earnings Growth Analysis

Earnings Trend: CSRT's earnings have grown by 2.7% per year over the past 5 years.

Accelerating Growth: CSRT's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: CSRT had negative earnings growth (-76.8%) over the past year, making it difficult to compare to the Medical Equipment industry average (-4.5%).


Return on Equity

High ROE: CSRT's Return on Equity (1.7%) is considered low.


Next Steps

Financial Health

How is Consort Medical's financial position?


Financial Position Analysis

Short Term Liabilities: CSRT's short term assets (£140.6M) exceed its short term liabilities (£76.9M).

Long Term Liabilities: CSRT's short term assets (£140.6M) do not cover its long term liabilities (£173.3M).


Debt to Equity History and Analysis

Debt Level: CSRT's debt to equity ratio (55.6%) is considered high.

Reducing Debt: CSRT's debt to equity ratio has increased from 1.3% to 55.6% over the past 5 years.

Debt Coverage: CSRT's debt is not well covered by operating cash flow (11.8%).

Interest Coverage: CSRT's interest payments on its debt are well covered by EBIT (8.8x coverage).


Balance Sheet

Inventory Level: CSRT has a high level of physical assets or inventory.

Debt Coverage by Assets: CSRT's debt is covered by short term assets (assets are 1.1x debt).


Next Steps

Dividend

What is Consort Medical's current dividend yield, its reliability and sustainability?

2.36%

Forecast Dividend Yield


Dividend Yield vs Market

Notable Dividend: Unable to evaluate CSRT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate CSRT's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if CSRT's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CSRT's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: CSRT is not paying a notable dividend for the UK market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of CSRT's dividend in 3 years as they are not forecast to pay a notable one for the UK market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.1yrs

Average management tenure


CEO

Mark Quick (53yo)

no data

Tenure

Mr. Mark Quick has been Chief Executive Officer at Consort Medical plc since February 2020. He serves as an Executive Vice President of Corporate Development at Recipharm AB and Recipharm AB (publ). Mr. Qu ...


Leadership Team

NamePositionTenureCompensationOwnership
Paul Hayes
CFO & Executive Director2.75yrsUK£635.00k0.024% £120.6k
Mark Quick
Chief Executive Officerno datano datano data
Kevin Cunningham
Vice President of Operations1.08yrsno datano data
Andrew Jackson
Group General Counsel & Company Secretary1.5yrsno datano data
Lisa King
Director of Human Resources11.5yrsno datano data
Colin Leeder
Group Financial Controllerno datano datano data
Keyvan Djamarani
Business President of Bespak Drug Delivery Devices2.08yrsno data0.051% £249.7k

2.1yrs

Average Tenure

Experienced Management: CSRT's management team is considered experienced (2.1 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Paul Hayes
CFO & Executive Director2.75yrsUK£635.00k0.024% £120.6k
William Jenkins
Senior Independent Director8.42yrsUK£66.16k0.0033% £16.3k
Ian Nicholson
Non-Executive Director7.67yrsUK£47.22k0.0048% £23.7k
Stephen Crummett
Non-Executive Director7.67yrsUK£50.13k0.0020% £10.1k
Andrew Hosty
Non Executive Director5.58yrsUK£44.51k0.0032% £16.0k
Thomas Eldered
Chairmanno datano datano data
Maria Ginman-Horrell
Non-Executive Director5yrsUK£42.03k0.0019% £9.5k

6.6yrs

Average Tenure

54yo

Average Age

Experienced Board: CSRT's board of directors are considered experienced (6.6 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: CSRT insiders have sold more shares than they have bought in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Consort Medical plc's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Consort Medical plc
  • Ticker: CSRT
  • Exchange: LSE
  • Founded: 1946
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: UK£493.441m
  • Shares outstanding: 49.10m
  • Website: https://www.consortmedical.com

Number of Employees


Location

  • Consort Medical plc
  • Breakspear Park
  • Suite B
  • Hemel Hempstead
  • Hertfordshire
  • HP2 4TZ
  • United Kingdom

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CSRTLSE (London Stock Exchange)YesOrdinary SharesGBGBPJan 1992
8C7BST (Boerse-Stuttgart)YesOrdinary SharesDEEURJan 1992
CSRTlBATS-CHIXE (BATS 'Chi-X Europe')YesOrdinary SharesGBGBPJan 1992

Biography

Consort Medical plc operates as a one-stop developer and manufacturer of drugs and premium drug delivery devices in Europe, the United States, the United Kingdom, and internationally. It operates through two segments, Bespak and Aesica. The company provides various life improving treatments to patients worldwide through the design, development, and manufacture of medical devices for inhaled, injectable, nasal, and ocular drug delivery, as well as point of care diagnostics products. It also develops, formulates, and manufactures active pharmaceutical ingredients, such as flurbiprofen, and finished dose drugs. Consort Medical plc was incorporated in 1946 and is based in Hemel Hempstead, the United Kingdom. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/17 20:39
End of Day Share Price2020/02/17 00:00
Earnings2019/10/31
Annual Earnings2019/04/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.